👀 Ones to watch: The MOST undervalued stocks to buy right nowSee Undervalued Stocks

CME Group's Q4 profit beats as interest-rate products lift trading volume

Published 02/14/2024, 07:15 AM
Updated 02/14/2024, 10:00 AM
© Reuters. CME Group Inc logo is seen displayed in this illustration taken April 10, 2023. REUTERS/Dado Ruvic/Illustration/File Photo
CME
-

By Arasu Kannagi Basil and Laura Matthews

(Reuters) - CME Group (NASDAQ:CME) reported a better-than-expected fourth-quarter profit on Wednesday, as strong demand for its interest-rate products bolstered trading volumes to give the derivatives exchange the strongest year in its history.

The U.S. Federal Reserve's interest rate hikes last year helped CME's average daily volume (ADV) hit a record high as customers increasingly hedged to manage their rate exposures and navigate uncertainty.

That helped CME's interest rate ADV surge 35.8% to 13.3 million contracts in the quarter, driven by record U.S. Treasury futures and options volumes.

The company has continued to benefit even amid a pause in rate hikes as customers needed to manage risk against the backdrop of diverging views about where the rates were heading.

CME Group Chief Executive Terry Duffy told analysts on a call that the exchanges' volumes are typically higher during periods of uncertainty about rates changes as is currently the case.

"I've never seen such a disparity in opinions on what the Fed may or may not do, and I believe that is a tailwind for CME Group in our rates products," Duffy said.

CME's total ADV surged 17% to 25.5 million contracts in the quarter. For 2023, it rose 5% to an annual record of 24.4 million contracts.

The demand for CME's hedging products has remained steady, driven by increased geopolitical and economic uncertainty, even as expectations grow for a soft landing for the U.S. economy.

ADV for CME's agricultural commodities products rose 25.5% from a year ago, while energy products volume jumped 18%.

Clearing and transaction fees, which make up the largest chunk of its revenue, jumped 20.7% to $1.18 billion, while total revenue surged 19.2% to $1.44 billion.

Revenue in its market data segment rose 9% in the fourth quarter to $167 million compared with the same period last year.

On an adjusted basis, CME's net income attributable to common shareholders rose to $853.8 million, or $2.37 per share, for the three months ended Dec. 31, compared with analysts' expectation of $2.28, according to LSEG data.

This was the 10th consecutive quarter of double-digit percentage growth in adjusted earnings, CME said.

© Reuters. CME Group Inc logo is seen displayed in this illustration taken April 10, 2023. REUTERS/Dado Ruvic/Illustration/File Photo

The exchange remains optimistic that transaction fee adjustments that took effect at various times earlier this year, will increase total revenue by up to 3%, should it see similar activity to 2023.

CME's share price was up 3.9% at $215.48 following the call.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.